These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24420746)

  • 1. Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.
    Kwara A; Cao L; Yang H; Poethke P; Kurpewski J; Tashima KT; Mahjoub BD; Court MH; Peloquin CA
    Pharmacotherapy; 2014 Mar; 34(3):265-71. PubMed ID: 24420746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers.
    Kwara A; Tashima KT; Dumond JB; Poethke P; Kurpewski J; Kashuba AD; Court MH; Greenblatt DJ
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3527-33. PubMed ID: 21518840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.
    Weiner M; Peloquin C; Burman W; Luo CC; Engle M; Prihoda TJ; Mac Kenzie WR; Bliven-Sizemore E; Johnson JL; Vernon A
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4192-200. PubMed ID: 20660695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.
    Kwara A; Yang H; Antwi S; Enimil A; Gillani FS; Dompreh A; Ortsin A; Opoku T; Bosomtwe D; Sarfo A; Wiesner L; Norman J; Alghamdi WA; Langaee T; Peloquin CA; Court MH; Greenblatt DJ
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 and Solute Carrier Organic Anion Transporter Family 1 Member B1 Polymorphisms and Efavirenz on Bilirubin Disposition in Healthy Volunteers.
    Collins KS; Metzger IF; Gufford BT; Lu JB; Medeiros EB; Pratt VM; Skaar TC; Desta Z
    Drug Metab Dispos; 2020 Mar; 48(3):169-175. PubMed ID: 31888882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
    Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
    PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.
    Dooley KE; Luetkemeyer AF; Park JG; Allen R; Cramer Y; Murray S; Sutherland D; Aweeka F; Koletar SL; Marzan F; Bao J; Savic R; Haas DW;
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5245-52. PubMed ID: 24957823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Genetic Variation of
    Dompreh A; Tang X; Zhou J; Yang H; Topletz A; Adu Ahwireng E; Antwi S; Enimil A; Langaee T; Peloquin CA; Court MH; Kwara A
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
    López-Cortés LF; Ruiz-Valderas R; Viciana P; Alarcón-González A; Gómez-Mateos J; León-Jimenez E; Sarasanacenta M; López-Pua Y; Pachón J
    Clin Pharmacokinet; 2002; 41(9):681-90. PubMed ID: 12126459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
    Niemi M; Pasanen MK; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel.
    Schilling U; Dingemanse J; Voors-Pette C; Romeijn C; Dogterom P; Ufer M
    Clin Transl Sci; 2020 Sep; 13(5):886-890. PubMed ID: 32166864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.
    Chigutsa E; Visser ME; Swart EC; Denti P; Pushpakom S; Egan D; Holford NH; Smith PJ; Maartens G; Owen A; McIlleron H
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4122-7. PubMed ID: 21709081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.
    Cho DY; Shen JH; Lemler SM; Skaar TC; Li L; Blievernicht J; Zanger UM; Kim KB; Shin JG; Flockhart DA; Desta Z
    Drug Metab Pharmacokinet; 2016 Apr; 31(2):107-16. PubMed ID: 27053325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
    Ramachandran G; Hemanth Kumar AK; Rajasekaran S; Kumar P; Ramesh K; Anitha S; Narendran G; Menon P; Gomathi C; Swaminathan S
    Antimicrob Agents Chemother; 2009 Mar; 53(3):863-8. PubMed ID: 19124658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
    Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability in plasma rifampicin concentrations and role of
    Sileshi T; Makonnen E; Telele NF; Barclay V; Zumla A; Aklillu E
    Infect Dis (Lond); 2024 Apr; 56(4):308-319. PubMed ID: 38315168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings.
    Ziesenitz VC; König SK; Mahlke N; Jantos R; Skopp G; Weiss J; Haefeli WE; Mikus G
    Basic Clin Pharmacol Toxicol; 2013 Jul; 113(1):43-8. PubMed ID: 23480028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
    Ogasawara K; Kam J; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):369-377. PubMed ID: 34019108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.
    Kohlrausch FB; de Cássia Estrela R; Barroso PF; Suarez-Kurtz G
    Br J Clin Pharmacol; 2010 Jan; 69(1):95-8. PubMed ID: 20078617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.